27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ:CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ:SPRC) has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO).
The patents cover psychedelic-based therapeutics, including monotherapy and novel combinations of SciSparc’s CannAmide and classical psychedelics.
More specifically, the patent applications refer to proprietary combinations of LSD, psilocybin, and DMT with SciSparc’s Palmitoylethanolamide (PEA), a cannabimimetic compound and the active ingredient of its proprietary CannAmide drug.
See also: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
The fruitful collaboration between both companies has previously led Clearmind to file three other U.S. patent applications, then for the combination of SciSparc’s PEA with Clearmind’s MEAI (5-methoxy-2-aminoindane) for treating Alcohol Use Disorder (AUD,) cocaine addiction, and obesity and its related metabolic disorders.
The new patent applications aim to make use of psychedelic substances that have shown positive clinical results together with CannAmide to potentially offer “a treatment that is more effective, safer, and at lower costs,” according to Clearmind CEO Adi Zuloff-Shani.
The strategy “aligns with the company's vision to bring patients the newest, most effective treatments while maintaining a high safety profile and a strong IP position to enhance commercial viability."
SpiSparc CEO Oz Adler says that the new patent applications continue to support the company’s findings of the major role CannAmide plays in SciSparc’s various proprietary combination treatments.
“All our clinical and pre-clinical studies performed to date, in numerous diseases and conditions, indicated CannAmide’s ability to reduce doses while maintaining therapeutic efficacy and increasing safety,” Adler detailed. “We have great confidence in our collaboration with Clearmind and believe that together we can maximize the therapeutic effect of our products, potentially offering additional solutions for mental health problems with unmet needs that have limited effective solutions, if at all.”
Photo: Benzinga edit with photo by Olia Danilevich on Pexels.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!